NCI sponsored, ECOG-ACRIN study advances after successful planned interim analysis

Lexington, MA – September 11, 2020 — Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces the resumption of enrollment in the National Cancer Institute (NCI) sponsored Study EA6141¹ being conducted by ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and led by Study Chair F. Stephen Hodi, MD, Director of the Center for Immuno-Oncology at Dana-Farber Cancer Institute and Study Co-Chair Ahmad Tarhini, MD, PhD., Professor of Oncologic Sciences and Director of Cutaneous ...

Study builds on extensive research showing that granulocyte-macrophage colony stimulating factor (GM-CSF) is needed for effective immune function in the lungs

iLeukPulm Phase 2 Clinical TrIal Supported by $35 Million Contract from U.S. Department of Defense

LEXINGTON, MA – August 25, 2020 — Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced today that the first patient has been enrolled in the iLeukPulm clinical trial, a randomized phase 2 study of inhaled Leukine (sargramostim, rhu-GM-CSF) in hospitalized COVID-19 patients with acute hypoxemia ...

Funding will support two randomized, multi-center clinical trials in COVID-19 patients, expansion of manufacturing capacity and potential Emergency Use Authorization (EUA) filing

LEXINGTON, MA – August 4, 2020 — Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, today anounced a $35 million milestone-based Other Transaction Agreement (OTA) with the U.S. Department of Defense (DOD) to fund two clinical studies of inhaled Leukine® (sargramostim, rhu-Granulocyte Macrophage-Colony Stimulating Factor “GM-CSF”) in patients with COVID-19 associated acute hypoxemia.  Through the DOD’s Chemical Biological Defense ...

LEXINGTON, MA. June 11, 2020 – Partner Therapeutics, a commercial biotechnology company, announces the enrollment of the first patient dosed in a Phase II investigator-initiated study evaluating the efficacy and safety of Leukine® (sargramostim, rhu-GM-CSF) in T cell replete HLA-mismatched haploidentical stem cell transplant recipients who are receiving post-transplant cyclophosphamide (NCT04237623).

The study will enroll patients with high risk hematologic malignancies who are the recipients of a haploidentical cell transplant. The trial will evaluate the effectiveness of Leukine compared to a matched ...

Trial expands global clinical research of Leukine in treatment of COVID-19 including multi-center trial underway in Belgium

Lexington, MA – May 28, 2020 — Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces the initiation of an investigator-initiated randomized, double-blind, placebo-controlled clinical trial of Leukine(sargramostim, rhu-GM-CSF) in patients with acute respiratory failure associated with COVID-19, conducted at Singapore General Hospital (NCT04400929).  The study will evaluate the effect of Leukine on lung function and other important patient outcomes.

“There is large ...

SARPAC trial initiated at the University Hospital Ghent in Belgium

Lexington, MA – March 24, 2020 /PRNewswire/ — Partner Therapeutics, Inc. (PTx) announced that Leukine^® (sargramostim, rhu-GM-CSF) is being assessed in the SARPAC trial (sargramostim in patients with acute hypoxic respiratory failure due to COVID-19 – EudraCT #2020-001254-22) at University Hospital Ghent to treat patients with respiratory illness associated with COVID-19.  Major medical centers in Germany, Italy and Spain are considering joining the study.  The study will evaluate the effect ...

Former Aeolus CEO will lead business development and government relations

LEXINGTON, Mass., Nov. 7, 2019 /PRNewswire/ — Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced today that it appointed John McManus to serve as the company’s Chief Business Officer. In his role as CBO, Mr. McManus will oversee business development activities and government relations for PTx and serve on the Company’s executive management team.

Mr. McManus has over 20 years of leadership experience in the biopharmaceutical industry that includes leading the ...

LEXINGTON, Mass., Sept. 19, 2019 /PRNewswire/ — Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Leukine® (sargramostim), a yeast-derived recombinant human granulocyte-macrophage colony stimulating factor (rhuGM-CSF), for the potential treatment of Stage IIb-IV melanoma.

Melanoma is the most aggressive form of skin cancer and rates of melanoma have been rising for the past 30 years. The American Cancer Society estimates 96,480 new melanoma cases will be ...

LEXINGTON, MA – Nov 6th, 2018/ PR Newswire/ – Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Leukine® (sargramostim), a yeast-derived recombinant human granulocyte-macrophage colony stimulating factor (rhu-GM-CSF), for the treatment of pulmonary alveolar proteinosis (PAP). Leukine works by stimulating the production of white blood cells including neutrophils, monocytes/macrophages and myeloid-derived dendritic cell and promoting their ability to function.

PAP is a rare syndrome characterized by ...

LEXINGTON, Mass., June 6, 2018 /PRNewswire/

Commercial-stage cancer biotech company, Partner Therapeutics, Inc. (PTx), announced the recent FDA approval of Leukine for the treatment of adult and pediatric patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome, or H-ARS). Leukine is the first drug for H-ARS to demonstrate an improvement in survival when initiated 48 hours after radiation exposure.

Acute Radiation Syndrome (ARS) (sometimes known as radiation toxicity or radiation sickness) is an acute illness caused by ...